In this study, researchers from the University of Barcelona, Spain, investigated whether the variable outcome of chronic hepatitis B was related to hepatitis B virus (HBV) genotype.
A team of researchers observed clinical and virologic events, over prolonged follow-up, in 258 Spanish patients. Patients had chronic hepatitis B and were infected with different genotypes of HBV.
The team found the prevalence of genotypes A, D, and F, were 52%, 35%, and 7%, respectively.
They also determined that concomitant sustained biochemical remission and clearance of HBV DNA occurred at a higher rate in genotype A, than in D or F-infected patients.
|Rate of hepatitis B surface antigen (HBsAg) clearance higher in HBV genotype A.|
In addition, the rate of hepatitis B surface antigen (HBsAg) clearance was higher in genotype A than in genotype D hepatitis.
Furthermore, sustained remission and clearance of HBsAg were associated with infection with genotype A by Cox regression analysis.
Seroconversion to antibody to hepatitis B e antigen (anti-HBe) was found to be unrelated to HBV genotype.
However, the rate of sustained remission after seroconversion was higher in genotype A than in genotype D hepatitis. This was true both in patients who seroconverted to anti-HBe during follow-up, and in patients with positive anti-HBe at baseline.
The team also found that liver disease-related death was more frequent in genotype F, than in either genotype A or D hepatitis.
Dr José Sánchez-Tapias's team concluded, "The long-term outcome of chronic hepatitis B is different in patients infected with HBV genotype A, D, or F".